Received Jun 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
suspected vaccination failure; shingles of right eye; shingles of top of head and forehead; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: suspected vaccination failure) (serious criteria GSK medically significant), ophthalmic herpes zoster (Verbatim: shingles of right eye) (serious criteria GSK medically significant) and facial herpes zoster (Verbatim: shingles of top of head and forehead). The outcome of the vaccination failure was unknown and the outcome of the ophthalmic herpes zoster and facial herpes zoster were resolving. The reporter considered the vaccination failure, ophthalmic herpes zoster and facial herpes zoster to be unrelated to Shingrix. The company considered the vaccination failure, ophthalmic herpes zoster and facial herpes zoster to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 07-JUN-2026 This case was reported by a patient via interactive digital media. The patient received both shots for shingles and now recovering from shingles of top of head and forehead and right eye and it was painful. The batch number was not provided and unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure and Ophthalmic herpes zoster, unknown time after receiving 2nd dose of Shingrix, in a male patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.